Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azacitidine in Lower-risk Myelodysplastic Syndromes
NCT01566695Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2013
- Primary completion
- Jan 2019
- Countries
- 23
01
Overview
A Phase 3 trial of CC-486 in myelodysplastic syndrome (MDS), sponsored by Celgene Corporation. Started Apr 2013; status: completed.
02
Drugs
CC-486
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01566695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01566695.